Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-03-22, Stock:LLY, The news for the past five days is as follows:
2018-03-15: NEWS1: Analysts’ Recommendations for Eli Lilly in March 2018.NEWS2: Update on Eli Lilly’s Oncology Drugs Erbitux, Gemzar, Lartruvo.NEWS3: Performance of Eli Lilly’s Oncology Drugs Alimta, Cyramza in 2017.NEWS4: Update on Eli Lilly’s Neuroscience Portfolio.NEWS5: Eli Lilly’s Immunology Business Saw Solid Growth in 2017.NEWS6: Eli Lilly’s Endocrinology Drugs Humalog, Humatrope, and Humulin.NEWS7: A Look at Eli Lilly’s Endocrinology Business in 2017.NEWS8: A Post-4Q17 Update on Eli Lilly’s Cardiovascular Business.NEWS9: Eli Lilly’s Jardiance, Trajenta, and Trulicity in 2017.NEWS10: Eli Lilly’s Performance in Fiscal 4Q17 and Fiscal 2017.NEWS11: Pfizer’s Valuation Post-4Q17 Earnings.NEWS12: How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment.NEWS13: How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment.NEWS14: How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment.NEWS15: Capitol to Capital: Cramer's 'Mad Money' Recap (Wednesday 3/14/18).
2018-03-16: NEWS1: Is Eli Lilly and Company (LLY) Stock a Good Value Pick Now?.NEWS2: Is Eli Lilly and Company (LLY) Stock a Good Value Pick Now?.NEWS3: Is Eli Lilly and Company (LLY) Stock a Good Value Pick Now?.NEWS4: How Pfizer Performed across Geographies during 4Q17.
2018-03-19: NEWS1: Qualcomm Ex-Chairman's Leveraged Buyout Bid a Real Long Shot.NEWS2: GlaxoSmithKline’s Valuation in March 2018.NEWS3: Radius Health Announces Positive Data on Lead Drug Tymlos.NEWS4: Radius Health Announces Positive Data on Lead Drug Tymlos.NEWS5: Notable ETF Inflow Detected - XLV, PFE, TMO, LLY.NEWS6: Notable ETF Inflow Detected - XLV, PFE, TMO, LLY.NEWS7: Reading Merck’s Animal Health in 2017: A Post-4Q17 Update.NEWS8: See what the IHS Markit Score report has to say about Eli Lilly And Co..
2018-03-20: NEWS1: Roche Tecentriq Phase III Combo Study Meets Primary Endpoint.NEWS2: Roche Tecentriq Phase III Combo Study Meets Primary Endpoint.NEWS3: CVS appoints former Eli Lilly CFO as president of PBM business.NEWS4: Understanding Nektar Therapeutics’ Top-Line Performance.NEWS5: CVS to Hire Former Eli Lilly CFO to Run Pharmacy Benefit Business.NEWS6: 3 High-Quality Dividend-Payers Selling at a Discount.
2018-03-21: NEWS1: After Hours Most Active for Mar 21, 2018 :  LC, HPE, OAS, BAC, LLY, RRC.NEWS2: After Hours Most Active for Mar 21, 2018 :  LC, HPE, OAS, BAC, LLY, RRC.NEWS3: Ignore Trump's Pricing Rhetoric With These 5 Biotech Picks.NEWS4: Ignore Trump's Pricing Rhetoric With These 5 Biotech Picks.NEWS5: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS6: A Look at Nektar Therapeutics’ Cash Flows.NEWS7: CVS to Hire Former Eli Lilly CFO to Run Pharmacy Benefit Business.

Answer: Decrease